ReGen Biologics Introduces New Brand Name and Websites

ReGen Biologics (OTC: RGBI) today announced the international
release of a new brand name - Menaflex(TM) - for its collagen meniscus
implant device and associated product web site, www.menaflex.com. "The
CMI(R) name was used during the research and development phase of the
Company´s collagen meniscus implant device, and it will continue to be
seen in numerous scientific publications and clinical references. Now
that we are marketing the product outside the United States, we will
utilize a unique brand name that allows for improved recognition among
patients and surgeons," stated Gerald E. Bisbee, Jr., Ph.D., Chairman
and Chief Executive Officer.

To advance international awareness and understanding of the
Menaflex product and the associated surgical procedure, the Company is
launching www.menaflex.com which provides a wealth of information
regarding knee and meniscus injuries and treatment options, including
the Menaflex procedure. The website was designed specifically for
patients around the world, and it incorporates local country
directories of surgeons trained in the Menaflex procedure, from which
potential patients can seek additional information and a specific
diagnosis.

The full transition to the Menaflex name will take approximately
three quarters as the Company works through current levels of
inventory on product and collateral materials.

Simultaneously with the launch of www.menaflex.com, the Company
has updated its corporate website (www.regenbio.com), which provides a
comprehensive overview of the Company and its technology, while also
serving as an excellent investor resource. Dr. Bisbee commented,
"Patients, surgeons and investors from around the world who are
interested in our Company and products can find the specific product
information for their locale and general information regarding ReGen
Biologics."

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen´s patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. ReGen´s first approved
product using its collagen scaffold technology is the Menaflex(TM)
meniscus application, which is cleared for sale in Europe and other
countries and marketed through ReGen´s European subsidiary, ReGen
Biologics AG. ReGen continues to work to obtain FDA clearance of the
Menaflex device in the United States.

ReGen has conducted the largest human clinical trial on an
arthroscopic meniscus procedure and the resulting database has unique
value in better understanding meniscus injuries. The Company is
headquartered in Hackensack, NJ and manufactures its collagen scaffold
products in its ISO Certified facility located in Redwood City, CA.
For more information on ReGen, visit www.regenbio.com .

This press release contains forward-looking statements within the
meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
current expectations and beliefs of the management of ReGen and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including those discussed in the Risk
Factors section of ReGen´s 2006 annual report on Form 10-K and
additional filings with the SEC. ReGen´s filings with the SEC are
available to the public at the Company´s website at
http://www.regenbio.com, from commercial document-retrieval services
and at the Web site maintained by the SEC at http://www.sec.gov .